All In Biotech

Drug Trial Radar · NCT00858637

Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis

A Phase III, Multicentre, Double-blind, Double-dummy, Randomised, Flexible-dose, Comparative Study of MCI-196 Versus Simvastatin for the Treatment of Dyslipidaemia in Subjects With Chronic Kidney Disease on Dialysis (Incorporating a Placebo-controlled Withdrawal Phase)

Last checked: Nov 20, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

260

Actual

Start

Mar 2009

Primary completion

Mar 2010

Study completion Mar 2010

Sponsor

Lead sponsor
Tanabe Pharma CorporationIndustry
Sponsor type
Industry
First posted
Mar 10, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to demonstrate the superiority of MCI-196 over placebo and non-inferiority with simvastatin in reducing serum low-density lipoprotein (LDL)-cholesterol in subjects with chronic kidney disease Stage V on dialysis. This study incorporates a Washout Period and two treatment periods - an active comparison phase and a placebo-controlled withdrawal phase.

Conditions

  • Chronic Kidney Disease

Interventions

  • MCI-196Drug

    Tablets of 3 g to 12 g/day (3 times a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)

  • Placebo of SimvastatinDrug

    Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)

  • SimvastatinDrug

    Tablets of 10 mg to 40 mg/day (once a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)

  • Placebo of MCI-196Drug

    Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Serum LDL-cholesterol Levels From Week 16 to Week 20 (LOCF) (ITT2)Time frame: week20 minus week16

Locations

39 sites in 13 countries. Site status is shown where the registry gives one.

  • Site not named

    Brest, Belarus

  • Site not named

    Grodno, Belarus

  • Site not named

    Homyel, Belarus

  • Site not named

    Minsk, Belarus

  • Site not named

    Vitebsk, Belarus

  • Site not named

    Gabrovo, Bulgaria

  • Site not named

    Plovdiv, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Karlovac, Croatia

  • Site not named

    Osijek, Croatia

  • Site not named

    Esbjerg, Denmark

  • Site not named

    Roskilde, Denmark

  • Site not named

    Jakarta, Indonesia

  • Site not named

    Malang, Indonesia

  • Site not named

    Medan, Indonesia

  • Site not named

    Palembang, Indonesia

  • Site not named

    Tamanlarea Makassar, Indonesia

  • Site not named

    Ashkelon, Israel

  • Site not named

    Nahariya, Israel

  • Site not named

    Bellano, Italy

  • Site not named

    Catania, Italy

  • Site not named

    Lecco, Italy

  • Site not named

    Merate, Italy

  • Site not named

    Milan, Italy

  • Site not named

    Oggiono, Italy

  • Site not named

    Riga, Latvia

  • Site not named

    Valmiera, Latvia

  • Site not named

    Kaunas, Lithuania

  • Site not named

    Kedauniai, Lithuania

  • Site not named

    Vilnius, Lithuania

  • Site not named

    George Town, Malaysia

  • Site not named

    Johor Bahru, Malaysia

  • Site not named

    Kelantan, Malaysia

  • Site not named

    Perak, Malaysia

  • Site not named

    Bucharest, Romania

  • Site not named

    Timișoara, Romania

  • Site not named

    Singapore, Singapore

  • Site not named

    Bangkok, Thailand

  • Site not named

    Phitsanulok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.